AcelRx Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.10.18	CORV Is Back, SENS' Eversense Gets Aetna Coverage, ACRX Nears FDA Decision Day (RTTNews)
15.10.18	FDA Panel Backs ACRX's Pain Drug, ALL Eyes On EARS, TNDM On Watch (RTTNews)
11.10.18	ACRX Nears D-day, TRVN On Watch, All's Well With CRSP, TearLab Disappointed (RTTNews)
07.10.18	Week Ahead In Pharmaceuticals: 6 Stocks To Watch (BPMC, BHC, ACRX...) (RTTNews)
03.10.18	AVRO Down 60% In 2 Days, MESO On Watch, ACRX Faces FDA Panel Next Week (RTTNews)
28.09.18	Biotech Stocks Facing FDA Decision In October (RTTNews)
25.09.18	AMRN Heartens Investors, AKCA On Watch, ACRX Faces FDA Panel In Oct. (RTTNews)
12.09.18	FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. (RTTNews)
12.07.18	AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3 (RTTNews)
28.06.18	ACRX Gets EC Nod, AQXP Tanks As LEADERSHIP 301 Fails, ZSAN Catches Eye (RTTNews)
24.05.18	AcelRx announces FDA acceptance of NDA for DSUVIA (PR Newswire)
23.05.18	Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures (PR Newswire)
22.05.18	AcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference (PR Newswire)
09.05.18	AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results (PR Newswire)
09.05.18	AcelRx resubmits New Drug Application for DSUVIA™ (PR Newswire)
30.04.18	AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems (PR Newswire)
27.04.18	AcelRx receives positive CHMP opinion for DZUVEO™ for management of acute moderate to severe pain in medically monitored settings (PR Newswire)
25.04.18	AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018 (PR Newswire)
18.04.18	AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored... (PR Newswire)
16.04.18	AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018 (PR Newswire)
11.04.18	AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe (PR Newswire)
27.03.18	AcelRx announces appointment of John Saia as General Counsel (PR Newswire)
27.03.18	EKSO Leaps, FDA Nod For DRIO, CRVS Up 38% This Month, VTL To Report Data In Sep. (RTTNews)
22.03.18	Blockchain Capital Closes Fund IV at $150 Million (PR Newswire)
09.03.18	FDA Panel Backs Xeljanz For UC, ACRX Abuzz, AGLE Awaits Data This Month (RTTNews)
08.03.18	AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results (PR Newswire)
08.03.18	AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018 (PR Newswire)
05.03.18	AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March (PR Newswire)
02.03.18	AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results Conference Call and Webcast on Thursday, March 8th, 2018 (PR Newswire)
16.02.18	AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference (PR Newswire)
08.01.18	Survey: Winter Workplace Blues Hit These Cities Most (PR Newswire)
29.11.17	Biotech Stocks Facing FDA Decision In December (RTTNews)
16.11.17	AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain (PR Newswire)
09.11.17	AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results (PR Newswire)
09.11.17	AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department (PR Newswire)
31.10.17	AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 9th (PR Newswire)
24.10.17	Lifshitz & Miller LLP Announces Investigation of AcelRx Pharmaceuticals, Inc., Bob Evans Farms, Inc., Calgon Carbon Corporation, Exa Corporation, Insulet Corporation, K12 Inc., PG&E Corporation (PR Newswire)
20.10.17	AcelRx's DSUVIA™ Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017 (PR Newswire)
16.10.17	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX (PR Newswire)
13.10.17	INFI Turns Heads, ARDX Marches On, VYGR Cruises Ahead, ACRX Disappoints (RTTNews)
12.10.17	AcelRx Remains Sharply Lower After Early Sell-Off (RTTNews)
12.10.17	AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA (PR Newswire)
03.10.17	ECYT On Fire After ABX Deal, Rigel's ITP Drug Skips Panel Review, MCRB On Watch (RTTNews)
29.09.17	Biotech Stocks Facing FDA Decision In October (RTTNews)
28.09.17	Actiance, Osterman Study Reveals True Costs of On-Premise Enterprise Vault Archive Solution (PR Newswire)
27.09.17	AXON Depressed By MINDSET, CDNA On Track, PTCT On A Sticky Wicket? (RTTNews)
26.09.17	ACRX Nearing 'Big Day', No Respite For VSAR, ARDM To Face FDA (RTTNews)
09.08.17	Matson Rated Among Top Ocean Carriers for 5th Consecutive Year (PR Newswire)
08.08.17	Medical Equipment Stock Performance Review -- Natus Medical, Masimo, Spectranetics, and AcelRx Pharma (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu AcelRx Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten